Abstract
It is known that the renin-angiotensin system (RAS) plays a fundamental role not only as a vasoconstrictor incontrolling blood pressure and electrolyte/fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1(AT1) receptor in smooth muscle cells and cardiac myocytes. Angiotensin II (Ang-II) is indeed thought to be a growthfactor, and Ang-II receptor blockers (ARBs), a class of antihypertensive agent, suppress signal transduction pathwaysmediated by several growth factors or cytokines, through the AT1 receptor. There is increasing evidence that the RAS isimplicated in the development of various cancers. We previously demonstrated that ARBs have the potential to inhibit thegrowth of prostate cancer cells and tumors through the AT1 receptor. This review highlights the possibility of ARBs asnovel agents for prostate cancer as well as other cancers, and reviews the literature on this area.
Keywords: Angiotensin II, renin-angiotensin system, angiotensin II receptor blocker, prostate cancer, hormone-refractorycancer
Mini-Reviews in Medicinal Chemistry
Title: Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Volume: 6 Issue: 7
Author(s): Hiroji Uemura, Hitoshi Ishiguro and Yoshinobu Kubota
Affiliation:
Keywords: Angiotensin II, renin-angiotensin system, angiotensin II receptor blocker, prostate cancer, hormone-refractorycancer
Abstract: It is known that the renin-angiotensin system (RAS) plays a fundamental role not only as a vasoconstrictor incontrolling blood pressure and electrolyte/fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1(AT1) receptor in smooth muscle cells and cardiac myocytes. Angiotensin II (Ang-II) is indeed thought to be a growthfactor, and Ang-II receptor blockers (ARBs), a class of antihypertensive agent, suppress signal transduction pathwaysmediated by several growth factors or cytokines, through the AT1 receptor. There is increasing evidence that the RAS isimplicated in the development of various cancers. We previously demonstrated that ARBs have the potential to inhibit thegrowth of prostate cancer cells and tumors through the AT1 receptor. This review highlights the possibility of ARBs asnovel agents for prostate cancer as well as other cancers, and reviews the literature on this area.
Export Options
About this article
Cite this article as:
Uemura Hiroji, Ishiguro Hitoshi and Kubota Yoshinobu, Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698633
DOI https://dx.doi.org/10.2174/138955706777698633 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Protein Microarray Technology
Combinatorial Chemistry & High Throughput Screening Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Quinolones in the Search for New Anticancer Agents
Current Pharmaceutical Design Azoles as Effective Antifungal Agents: Trends, Scope and Relevance
The Natural Products Journal Guaraná a Caffeine-Rich Food Increases Oxaliplatin Sensitivity of Colorectal HT-29 Cells by Apoptosis Pathway Modulation
Anti-Cancer Agents in Medicinal Chemistry Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design The Role of Culture and Ethnicity in the Adjustment to Gynecological Cancer
Current Women`s Health Reviews Recent Advances in the Analyses of Carotenoids and Their Role in Human Health
Current Pharmaceutical Analysis Multi-Target QSAR and Docking Study of Steroids Binding to Corticosteroid-Binding Globulin and Sex Hormone-Binding Globulin
Current Computer-Aided Drug Design The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Synthesis and Cytotoxicities of 2-[4-hydroxy-(3,5-bis-aminomethyl)- benzylidene]-indan-1-ones
Letters in Drug Design & Discovery Multiple Hsp70 Isoforms in the Eukaryotic Cytosol: Mere Redundancy or Functional Specificity?
Current Genomics Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Current Pharmaceutical Design Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Epigenetic Regulation and Therapeutic Approaches in Cancer
Current Topics in Medicinal Chemistry